I in cells of thyroid origin, after the ablation of residual normal thyroid tissue, being suYcient to result in tumour eradication. Unfortunately the thyroid is unique and targeted radioiodine treatment for other tumours requires specific vectors to carry the 'warhead'.With the development of monoclonal antibodies in 1975 3 it was hoped that Erlich's concept of an immunological magic bullet would quickly be realised, but more than 20 years later the applications of targeted monoclonal antibody treatment are distinctly limited in clinical oncology. There are several reasons for this failure of monoclonal antibodies to produce results: firstly, antigen expression on tumour cells is variable and tumour antigens are often expressed to some degree on normal cells, so the specificity is poor. Furthermore there is often poor penetration of large immune globulin molecules into tumours, a problem which has not been overcome to any significant degree by employing smaller molecular weight fragments. Furthermore murine monoclonal antibodies are themselves immunogenic and this precludes repeated administration. Despite these limitations, there have been attempts to employ targeted monoclonals in the treatment of neuroblastoma 4 5 and regional targeting of leukaemia within the cerebrospinal fluid 6 has produced responses. The search has continued for low molecular weight compounds, which utilise metabolic pathways with high tumour specificity. Currently one of the most promising compounds is metaiodobenzylguanidine (mIBG) which exploits the active uptake pathway for noradrenaline expressed in sympathetic nervous tissues and in tumours of neural crest origin. Radioiodinated adrenergic blocking agents were originally developed as adrenomedullary imaging agents 7 and the first human studies were described in adults with phaeochromocytoma 8 and soon after in children with neuroblastoma. 9 Laboratory studies have elucidated the mechanism of uptake of mIBG in neural crest tumours, while clinical studies have exploited the high aYnity of 131 I-mIBG for neuroblastoma in particular and targeted treatment is now moving into front line investigational protocols in Europe.
Laboratory studies
The mechanisms of uptake and retention of radioiodinated mIBG in tissues and tumours of neural crest origin have been extensively studied. 10 The cellular uptake of both noradrenaline and mIBG into adrenomedullary cells and neuroblastoma takes place both by a specific uptake system, known as uptake-one, and by a non-specific mechanism, presumed to be passive diVusion. Uptake-one is an active process by the noradrenaline transport transmembrane protein and is an high aYnity, saturable, sodium, energy, and temperature dependent process, which is sensitive to ouabain and competitively blocked by sympathomimetics such as imipramine. 11 In contrast the non-specific uptake system is energy independent, ouabain insensitive, and unsaturable at concentrations of at least 5 mM. Not all neuroblastoma cell lines possess the active transport mechanism, but in the human SK-N-SH neuroblastoma cell line specific uptake is >95% of total uptake at a concentration of 10 nM and is still 80% at the saturation concentration. 12 As plasma concentrations of mIBG after therapeutic doses are <0.1 µM, it is likely that in the clinical setting uptake-one is the predominant uptake system for mIBG. There are important diVerences in the uptake and storage of mIBG between neuroblastoma and phaeochromocytoma as demonstrated by comparative studies of PC-12 (phaeochromocytoma) and SK-N-SH (neuroblastoma) cell lines: storage in PC-12 cells is predominantly in the abundant neurosecretory granules and can be depleted by reserpine. In contrast, with SK-N-SH cells, where neurosecretory cells are sparse, the uptake is in the cytoplasm. 13 The potent depletion of mIBG in SK-N-SH cells by the uptake-one inhibitor, imipramine, suggests that retention of mIBG is the result of reuptake of mIBG that has passively diVused out of cells.
Pharmacological manipulation to enhance uptake and/or retention of mIBG in neuroblastoma cell lines has been unsuccessful with nifedipine or reserpine. Pretreatment with other agents, however, may exert an eVect and interferon has been shown to improve retention in vitro.
14 A recent fortuitous observation of up-regulation of the noradrenaline transporter and enhanced uptake of mIBG after cisplatin pretreatment of the neuroblastoma cell line SK-N-BE may, if confirmed in vivo, have clinical importance in the scheduling of multimodal treatment. 15 The distribution of mIBG in surgically excised human neuroblastoma tumours has been studied 24-48 hours after intravenous administration of 125 I-mIBG: an inhomogeneous distribution within individual tumours was found, with the most avid uptake in areas of viable undiVerentiated neuroblasts. 16 A study of the intracellular distribution of mIBG in human SK-N-SH neuroblastoma cell lines, xenografted into nude mice, by means of microautoradiography and secondary ion mass spectrometry microscopy, confirmed highly non-uniform distribution and, at an intracellular level, most of the radiopharmaceutical accumulated in the cytosol and perinuclear areas. 17 These observations are of importance in selecting the most appropriate radionuclide emitter(s) for use in targeted treatment.
Radiobiology
Neuroblastoma is one of the most radiosensitive of all human tumours 18 and external beam radiotherapy is employed with good benefit in the local control of disease, but the dose constraints of total body irradiation (TBI) preclude eVective systemic radiotherapy. Even the combination of TBI with high dose chemotherapy and autologous bone marrow rescue has failed to show any benefit over high dose chemotherapy alone. 19 If higher radiation doses could be delivered to the tumour while sparing normal tissues, radiotherapy has curative potential in this disease.
The radiobiological considerations that determine the eYcacy of radioiodinated mIBG in neuroblastoma have also been both modelled and studied. 20 21 Radiation induced cell death is generally assumed to result from lethal damage to the nucleus. As the cellular diameter of a neuroblast is 10-20 µm and as the particulate emission from 131 I has a mean range of 800 µm, this will result in a 'crossfire' eVect from adjacent cells that take up mIBG into cells that do not. This would be predicted to be advantageous in non-homogeneous tumours and, at the same time, potentially disadvantageous for example in the case of marrow infiltration where adjacent haematopoietic cells would be within range.
125
I emits Auger electrons with a range of ∼1 µm and would therefore not exert any 'crossfire' eVect, but ideally should be taken into the nucleus to exert maximum eVect. 125 I mIBG has been used for therapy at the University of Michigan. 22 An emitting radionuclide would, in theory at least, be ideal. 23 211
At-metaastatobenzylguanidine has been synthesised and has been shown to induce in vitro cytotoxicity much more efficiently than 131 I-mIBG, 24 however there are major logistical problems related to production and safety that will probably preclude this agent for in vivo human treatment.
Another important variable in mIBG treatment is the specific activity of the radiopharmaceutical. Commercially available 131 I-mIBG is of relatively low specific activity, that is the ratio of cold to radiolabelled molecules is high, and the cold molecules will compete for binding sites resulting in suboptimal tumour concentrations. Methods now exist for synthesis of high specific activity (or no carrier added) 131 I-mIBG. 25 The high specific activity preparation is be expected to enhance tumour uptake by a factor of around 10 as a result of improved target-to-background ratios, 26 but large scale production is thought not be commercially viable at the present time.
Mathematical modelling predicts that 131 I-mIBG would be most eVective in smaller micrometastases. The ideal size is predicted to contain ∼10 6 cells, with a lower cell kill in micrometastases smaller or larger than this. A study of spheroids of the human neuroblastoma cell line SK-H-BE (2c) of 250 µm and 400 µm size incubated in 131 I-mIBG has shown that the larger size spheroids had a greater vulnerability as predicted by the model. 21 It may well be that targeted 131 I-mIBG therapy can 'fill the gap' between chemotherapy, which is most eVective in very small micrometastases, and external beam radiotherapy and surgery, which are more eYcient in dealing with macroscopic tumours. These observations are also relevant to the sequencing of multimodal treatment and predict that targeted 131 I-mIBG treatment should be employed earlier rather than later in relation to chemotherapy.
Clinical studies
Neuroblastoma remains the major therapeutic challenge in paediatric oncology and new treatment strategies are needed. Despite response rates of approximately 75% with modern dose intensive induction chemotherapy and high dose consolidation with stem cell rescue, no more than 25% of children over 1 year of age at diagnosis of metastatic neuroblastoma will be long term survivors. 19 By 1991 reports had documented more than 250 children with advanced neuroblastoma who had received 131 I-mIBG treatment. 27 All of these treatments had been given to patients with chemoresistant disease either after induction chemotherapy or at relapse. Although the indications for treatment, methods of administration and criteria for assessment of response were variable, three of these earlier studies will be singled out:
(1) A phase II study from the Netherlands Cancer Institute reported on 53 patients with progressive or recurrent disease in whom conventional treatment had failed. 28 Empirical therapeutic activities of 3.7-7.4 GBq were given and some received more than one treatment. The results showed complete responses in 7/53 patients (13%), partial responses (>50% reduction in tumour volume) in 23/53 (43%), and stable disease in a further 10 patients (19%).
(2) The German Neuroblastoma Trial published results on 47 children who progressed or relapsed after treatment with standard chemotherapy. 29 Patients received 1-6 courses of 131 I-mIBG (mean total activity 14.4 GBq). The results showed that 9/47 patients (19%) achieved a complete or very good partial response, and a partial response was seen in a further 13 patients (28%).
(3) The prospective United Kingdom Children's Cancer Study Group (UKCCSG) phase I/II study, which was a dose finding and toxicity study of 131 I-mIBG therapy in stage 4 patients with a poor response to chemotherapy, reported partial responses in 8/24 patients (33%). 30 These three studies demonstrate that mIBG has single agent eYcacy comparable with that of the chemotherapy drugs presently employed in induction protocols.
Two studies have reported the feasibility of administering the maximum tolerated activity of 131 I-mIBG in combination with high dose chemotherapy and stem cell rescue as consolidation treatment. One study used 131 I-mIBG (average activity 11.1 GBq) followed by high dose carboplatin and melphalan, 31 while the other incorporated total body irradiation and no additive extramedullary toxicities were encountered. 32 The dose limiting toxicity of 131 I-mIBG when administered after intensive chemotherapy is thrombocytopenia. 30 Risk factors for the development of severe thrombocytopenia in this setting include bone marrow infiltration, prior intensive chemotherapy, and renal impairment. 33 An important single centre study of mIBG as first line treatment for high risk neuroblastoma was started in Amsterdam in 1991. 34 An interim report describes the first 31 children with inoperable neuroblastoma treated with a minimum of two cycles of 131 I-mIBG (7.4 GBq followed by 3.7 GBq). Thereafter, operability was assessed and, if the primary tumour was deemed unresectable, further fractions of 3.7 GBq of 131 I-mIBG were administered. Chemotherapy was reserved for those who failed to become operable after repeated 131 I-mIBG treatments (7/31) and for those with residual disease after surgical resection of the primary tumour. Isolated depression of the platelet count was seen in only 11 patients, while two patients developed pancytopenia. Severe thrombocytopenia was not encountered despite extensive bone marrow infiltration in some of these patients. The treatment was extremely well tolerated with virtually no sickness, no hair loss, and a mean weight gain of 9.5% between diagnosis and surgery. Eighty one per cent responded at metastatic sites and 73% responded at the primary site. Only 8/31 had an inadequate response to 131 I-mIBG treatment and went onto chemotherapy. At surgery 16/31 had a >95% resection and 3/31 a partial resection of their tumour. 35 
Future strategies
The radiobiological considerations predict that the combination of mIBG and chemotherapy administered as initial treatment for neuroblastoma would be the optimum clinical strategy. 20 At least in vitro, synergy can be demonstrated between external beam radiation treatment and platinum derivatives. 36 Pretreatment with cisplatin might enhance mIBG uptake into neuroblasts. 15 The feasibility of treating children with a mIBG/cisplatin combination has been reported in relapsed neuroblastoma, 37 but the optimum sequence and dose in newly diagnosed patients has still to be determined.
The UKCCSG is engaged in a multicentre pilot phase I study in poor prognosis newly diagnosed patients. This is essentially a feasibility and dose finding study of mIBG administered as initial treatment five days before the standard OPEC/OJEC chemotherapy protocol. The aim is to perform whole body dosimetry at the time of the diagnostic 123 I-mIBG scan in order to calculate the activity of 131 I-mIBG that will deliver the required whole body dose. The logistics of delivering targeted radiotherapy within two weeks of diagnosis in young children, who are systemically ill and need to be nursed in a radiation protected environment with limited parental contact for several days, are considerable but can be surmounted by having the radiation facility within the paediatric oncology ward. The principle is to employ the maximum tolerated dose of 131 ImIBG and the haematological and any other toxicity of a starting whole body dose of 1.5 Gy will be determined before dose escalation. The aim is to set up a national randomised trial in stage 4 neuroblastoma, possibly in collaboration with other European groups, to compare the remission rate induced by the current most eVective chemotherapy with that of combined treatment.
Conclusions
Although it is more than 10 years since mIBG was first used to treat neuroblastoma, there is still some way to go before the therapy is optimised. There is considerable potential for this modality to improve the results of treatment of advanced stage neuroblastoma, but it is too soon to know which of the new strategies employing mIBG will be the most eVective in achieving sustained remissions. It is clear that the short term toxicity is considerably less than that of current chemotherapy regimens, but there is a need to be vigilant for the possible long term toxicities of 131 I-mIBG treatment and, although there are few long term survivors to date, there is already one report of late thyroid dysfunction. 38 There is also a theoretical risk of radiation damage to the bladder wall, radiation induced secondary malignancy, and adrenal insuYciency consequent to high dose targeted radioiodine treatment. 
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